SLXN stock forecast models from equity research desks factor in a price-to-earnings ratio that remains below the industry median, potentially signaling room for upward re-rating if growth catalysts materialize in H2 Silexion Therapeutics (SLXN) Stock Forecast & Price Target Silexion Therapeutics (NASDAQ: SLXN) , una biotech in fase clinica specializzata in terapie basate su RNA interference per tumori guidati da KRAS, ha comunicato il prezzo di un' offerta pubblica da $6,0 milioni . L'offerta comprende 1.500.000 azioni ordinarie (o equivalenti) corredate da warrant di serie A e B al prezzo di $4,00 per azione . According to market trackers, SLXN stock forecast for the coming months reflects potential breakout behavior if key resistance at $15.50 clears, with Fibonacci retracement levels suggesting a 12% upside probability within Q3